Abstract
Introduction: Programmed death-1 ligand (PD-L1) has been often studied in different types of renal-cell carcinoma (RCC). For example, in clear-cell renal carcinoma it is well established that programmed death-1 receptor and PD-L1 are important prognostic markers. In contrast, the role of programmed death-2 ligand (PD-L2) as prognostic marker remains unclear. The aim of this study was to evaluate if PD-L2 expression could play a role as a prognostic marker for papillary RCC (pRCC). Methods: The patients’ sample collection was a joint collaboration of the PANZAR consortium. Patients’ medical history and tumor specimens were collected from n = 240 and n = 128 patients with type 1 and 2 pRCC, respectively. Expression of PD-L2 was determined by immunohistochemistry. In total, PD-L2 staining was evaluable in 185 of 240 type 1 and 99 of 128 type 2 pRCC cases. Results: PD-L2 staining was positive in 67 (36.2%) of type 1 and in 31 (31.3%) of type 2 pRCC specimens. The prevalence of PD-L2+ cells was significantly higher in high-grade type 1 tumors (p = 0.019) and in type 2 patients with metastasis (p = 0.002). Kaplan-Meier analysis disclosed significant differences in 5-year overall survival (OS) for patients with PD-L2− compared to PD-L2+ in pRCC type 1 of 88.4% compared to 73.6% (p = 0.039) and type 2 of 78.8% compared to 39.1% % (p < 0.001). However, multivariate analysis did not identify the presence of PD-L2+ cells neither in type 1 nor type 2 pRCC as an independent predictor of poor OS. Discussion/Conclusion: PD-L2 expression did not qualify as an independent prognostic marker in pRCC. Future studies will have to determine whether anti-PD-L2-targeted treatment may play a role in pRCC and expression can potentially serve as a predictive marker for these therapeutic approaches.
References
1.
Erlmeier
F
, Weichert
W
, Autenrieth
M
, Wiedemann
M
, Schrader
AJ
, Hartmann
A
, PD-L2: a prognostic marker in chromophobe renal cell carcinoma?
Med Oncol
. 2017 May
;34
(5
):71
.2.
Brahmer
JR
, Tykodi
SS
, Chow
LQ
, Hwu
WJ
, Topalian
SL
, Hwu
P
, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
. N Engl J Med
. 2012 Jun 28
;366
(26
):2455
–65
.3.
Topalian
SL
, Hodi
FS
, Brahmer
JR
, Gettinger
SN
, Smith
DC
, McDermott
DF
, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
. N Engl J Med
. 2012 Jun 28
;366
(26
):2443
–54
.4.
Ishida
Y
, Agata
Y
, Shibahara
K
, Honjo
T
. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death
. EMBO J
. 1992 Nov
;11
(11
):3887
–95
. .5.
Latchman
Y
, Wood
CR
, Chernova
T
, Chaudhary
D
, Borde
M
, Chernova
I
, PD-L2 is a second ligand for PD-1 and inhibits T cell activation
. Nat Immunol
. 2001 Mar
;2
(3
):261
–8
.6.
Terme
M
, Ullrich
E
, Aymeric
L
, Meinhardt
K
, Desbois
M
, Delahaye
N
, IL-18 induces PD-1-dependent immunosuppression in cancer
. Cancer Res
. 2011 Aug 15
;71
(16
):5393
–9
.7.
Abbas
M
, Steffens
S
, Bellut
M
, Becker
JU
, Großhennig
A
, Eggers
H
, Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?
Med Oncol
. 2016 Jun
;33
(6
):59
.8.
Erlmeier
F
, Hartmann
A
, Autenrieth
M
, Wiedemann
M
, Ivanyi
P
, Steffens
S
, PD-1/PD-L1 expression in chromophobe renal cell carcinoma: an immunological exception?
Med Oncol
. 2016 Nov
;33
(11
):120
.9.
Pardoll
DM
. The blockade of immune checkpoints in cancer immunotherapy
. Nat Rev Cancer
. 2012 Mar 22
;12
(4
):252
–64
. .10.
Shin
SJ
, Jeon
YK
, Kim
PJ
, Cho
YM
, Koh
J
, Chung
DH
, Clinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell carcinoma: association with oncogenic proteins status
. Ann Surg Oncol
. 2016 Feb
;23
(2
):694
–702
.11.
Moch
H
, Cubilla
AL
, Humphrey
PA
, Reuter
VE
, Ulbright
TM
. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours
. Eur Urol
. 2016 07
;70
(1
):93
–105
. .12.
Delahunt
B
, Eble
JN
, McCredie
MR
, Bethwaite
PB
, Stewart
JH
, Bilous
AM
. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases
. Hum Pathol
. 2001 Jun
;32
(6
):590
–5
. .13.
Pignot
G
, Elie
C
, Conquy
S
, Vieillefond
A
, Flam
T
, Zerbib
M
, Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification
. Urology
. 2007 Feb
;69
(2
):230
–5
.14.
Linehan
WM
, Spellman
PT
, Ricketts
CJ
, Creighton
CJ
, Fei
SS
, Davis
C
, Comprehensive molecular characterization of papillary renal-cell carcinoma
. N Engl J Med
. 2016 Jan 14
;374
(2
):135
–45
.15.
Steffens
S
, Schrader
AJ
, Blasig
H
, Vetter
G
, Eggers
H
, Tränkenschuh
W
, Caveolin 1 protein expression in renal cell carcinoma predicts survival
. BMC Urol
. 2011 Dec 07
;11
:25
.16.
Steffens
S
, Schrader
AJ
, Vetter
G
, Eggers
H
, Blasig
H
, Becker
J
, Fibronectin 1 protein expression in clear cell renal cell carcinoma
. Oncol Lett
. 2012 Apr 01
;3
(4
):787
–90
.17.
Theodorescu
D
, Broder
SR
, Boyd
JC
, Mills
SE
, Frierson
HF
. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate
. Cancer
. 1997 Dec 1
;80
(11
):2109
–19
. .18.
Abbas
M
, Steffens
S
, Bellut
M
, Eggers
H
, Großhennig
A
, Becker
JU
, Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC)
. Med Oncol
. 2016 Jul
;33
(7
):80
.19.
Bray
F
, Ferlay
J
, Soerjomataram
I
, Siegel
RL
, Torre
LA
, Jemal
A
. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
. CA Cancer J Clin
. 2018 11
;68
(6
):394
–424
. .20.
Tanegashima
T
, Togashi
Y
, Azuma
K
, Kawahara
A
, Ideguchi
K
, Sugiyama
D
, Immune suppression by PD-L2 against spontaneous and treatment-related antitumor immunity
. Clin Cancer Res
. 2019 8 1
;25
(15
):4808
–19
.21.
Wang
Q
, Zhang
J
, Tu
H
, Liang
D
, Chang
DW
, Ye
Y
, Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients
. J Immunother Cancer
. 2019 11 29
;7
(1
):334
.22.
Zhang
X
, Yin
X
, Zhang
H
, Sun
G
, Yang
Y
, Chen
J
, Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma
. BMC Cancer
. 2019 Apr 16
;19
(1
):360
.23.
Lu
Y
, Song
Y
, Xu
Y
, Ou
N
, Liang
Z
, Hu
R
, The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients
. Transl Androl Urol
. 2020 Apr
;9
(2
):367
–81
.24.
Seliger
B
. Basis of PD1/PD-L1 therapies
. J Clin Med
. 2019 Dec 08
;8
(12
):2168
. .25.
Baumeister
SH
, Freeman
GJ
, Dranoff
G
, Sharpe
AH
. Coinhibitory pathways in immunotherapy for cancer
. Annu Rev Immunol
. 2016 May 20
;34
:539
–73
. .26.
Trpkov
K
, Hes
O
, Williamson
SR
, Adeniran
AJ
, Agaimy
A
, Alaghehbandan
R
, New developments in existing WHO entities and evolving molecular concepts: the Genitourinary Pathology Society (GUPS) update on renal neoplasia
. Mod Pathol
. 2021 7
;34
(7
):1392
–424
.27.
Lobo
J
, Ohashi
R
, Helmchen
BM
, Rupp
NJ
, Rüschoff
JH
, Moch
H
. The morphological spectrum of papillary renal cell carcinoma and prevalence of provisional/emerging renal tumor entities with papillary growth
. Biomedicines
. 2021 Oct 9
;9
(10
):1418
. .28.
Herrmann
E
, Trojan
L
, Becker
F
, Wülfing
C
, Schrader
AJ
, Barth
P
, Prognostic factors of papillary renal cell carcinoma: results from a multi-institutional series after pathological review
. J Urol
. 2010 Feb
;183
(2
):460
–6
.29.
Bellut
J
, Bertz
S
, Nolte
E
, Stöhr
C
, Polifka
I
, Lieb
V
, Differential prognostic value of MYC immunohistochemistry in subtypes of papillary renal cell carcinoma
. Sci Rep
. 2017 Nov 27
;7
(1
):16424
.30.
Polifka
I
, Agaimy
A
, Herrmann
E
, Spath
V
, Trojan
L
, Stöckle
M
, High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma
. Hum Pathol
. 2019 01
;83
:212
–23
.© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
